| ID | Sequence | Length | GC content |
|---|---|---|---|
| GUGCUGUCACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUC… | 1879 nt | 0.6009 | |
| ACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUC… | 1685 nt | 0.5941 | |
| ACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUC… | 3541 nt | 0.5024 | |
| ACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUC… | 3638 nt | 0.5066 | |
| ACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUC… | 1783 nt | 0.5687 | |
| ACGUGAUCCGACAAACGGCCUCUGCAUAGUGCAGAACAUUCUGCUGCUC… | 3718 nt | 0.5083 |
This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008]
A study in humans demonstrated that the CLN3 (CLN3) was identified as a top-scoring single-gene blood biomarker capable of differentiating methamphetamine dependents without psychosis from those with methamphetamine-associated psychosis (MAP) with high accuracy [Breen et al. DOI:10.1038/tp.2016.67]. This biomarker, involved in lysosome function and RNA degradation, was validated through a convergent functional genomics approach and was part of a machine-learning classifier that achieved 95% accuracy in distinguishing these clinical groups.